Natalie Stieltjes

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Whole F8 gene sequencing identified pathogenic structural variants in the remaining unsolved patients with severe hemophilia A.

Whole F8 gene sequencing identified pathogenic structural variants in the remaining unsolved patients with severe hemophilia A.

Journal: Journal of thrombosis and haemostasis : JTH

Published: December 18, 2023

Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study.

Obstetrical complications in hereditary fibrinogen disorders: the Fibrinogest study.

Journal: Journal of thrombosis and haemostasis : JTH

Published: February 20, 2023

Reinvestigation of unidentified causative variants in FXI-deficient patients: Focus on gene segment deletions.

Reinvestigation of unidentified causative variants in FXI-deficient patients: Focus on gene segment deletions.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 29, 2022

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.

Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.

Journal: Human gene therapy

Published: February 14, 2022

Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors

Assessment of the impact of pharmaceutical consultations at initiation of a treatment with emicizumab in patients with severe hemophilia A without inhibitors

Journal: Annales pharmaceutiques francaises

Published: July 12, 2021

Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.

Pharmacodynamics of eftrenonacog-alfa (rFIX-Fc) in severe hemophilia B patients: A real-life study.

Journal: European journal of pharmacology

Published: August 03, 2020

Cost of clotting factors in hospitalization

Cost of clotting factors in hospitalization

Journal: Annales pharmaceutiques francaises

Published: October 28, 2017

Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Postauthorization safety study of Clottafact® , a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study.

Journal: Vox sanguinis

Published: May 23, 2017

Dermatologic surgery, hemophilia and Von Willebrand disease

Dermatologic surgery, hemophilia and Von Willebrand disease

Journal: Annales de dermatologie et de venereologie

Published: May 04, 2017

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia?

Is there a role for antiangiogenic therapy, bevacizumab, in the treatment of recurrent digestive bleeding due to angiodysplasia in Glanzmann's thrombasthenia?

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 07, 2016

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience.

Rituximab as first-line therapy for acquired haemophilia A: a single-centre 10-year experience.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: April 01, 2016

Post-authorization safety study of Clottafact® , a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study.

Post-authorization safety study of Clottafact® , a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study.

Journal: Vox sanguinis

Published: December 30, 2015

Showing 1-12 of 12

Last Updated: 09/26/2026